We are live on ! Find out more
DB

Dmitry Balyasny Balyasny Asset Management

AUM $80.2B
1-Year Est. Return 51.53%
 

Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.

This Fund
S&P 500
This Quarter Est. Return
+1.9%
1 Year Est. Return
+51.53%
3 Year Est. Return
+149.76%
5 Year Est. Return
+199.37%
10 Year Est. Return
+1,172.21%
AUM
$16.8B
AUM Growth
+$2.43B
Cap. Flow
+$2.2B
Cap. Flow %
13.07%
Top 10 Hldgs %
12.03%
Holding
1,764
New
564
Increased
341
Reduced
326
Closed
526

Top Buys

Rank Stock Value
1
MPC icon
Marathon Petroleum
MPC
+$152M
2
T icon
AT&T
T
+$119M
3
NSC icon
Norfolk Southern
NSC
+$117M
4
CSX icon
CSX Corp
CSX
+$115M
5
BKNG icon
Booking.com
BKNG
+$104M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 18.4%
2 Industrials 9.75%
3 Financials 7.9%
4 Consumer Staples 7.89%
5 Healthcare 7.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HVT icon
1376
Haverty Furniture Companies
HVT
$430M
-14,130
Closed -$303K
HXL icon
1377
Hexcel
HXL
$7B
-91,047
Closed -$4.23M
PPLI
1378
People Inc
PPLI
$2.89B
-33,544
Closed -$360K
IBM icon
1379
CALL
IBM
IBM
$218B
-52,300
Closed -$6.88M
IDXX icon
1380
Idexx Laboratories
IDXX
$44.1B
-5,000
Closed -$360K
IFF icon
1381
International Flavors & Fragrances
IFF
$21.9B
-3,360
Closed -$402K
IMMR icon
1382
Immersion
IMMR
$250M
-20,160
Closed -$235K
INFY icon
1383
CALL
Infosys
INFY
$47.9B
-200,000
Closed -$1.68M
INO icon
1384
Inovio Pharmaceuticals
INO
$129M
-2,992
Closed -$241K
INTC icon
1385
CALL
Intel
INTC
$461B
-100,000
Closed -$3.44M
INTC icon
1386
Intel
INTC
$461B
-6,200
Closed -$190K
IONS icon
1387
Ionis Pharmaceuticals
IONS
$10.3B
-185,954
Closed -$11.5M
ITT icon
1388
ITT
ITT
$18.3B
-92,184
Closed -$3.35M
JAKK icon
1389
Jakks Pacific
JAKK
$292M
-2,226
Closed -$177K
JBLU icon
1390
JetBlue
JBLU
$1.87B
-333,685
Closed -$7.56M
JBL icon
1391
CALL
Jabil
JBL
$31.9B
-150,000
Closed -$3.49M
JCI icon
1392
Johnson Controls International
JCI
$86.6B
-90,271
Closed -$3.73M
JD icon
1393
PUT
JD.com
JD
$39.4B
-75,000
Closed -$2.42M
JLL icon
1394
Jones Lang LaSalle
JLL
$17.8B
-3,058
Closed -$489K
JNPR
1395
DELISTED
Juniper Networks
JNPR
-14,808
Closed -$370K
JPM icon
1396
JPMorgan Chase
JPM
$947B
-50,000
Closed -$2.92M
JWN
1397
CALL
DELISTED
Nordstrom
JWN
-100,000
Closed -$4.98M
KALU icon
1398
Kaiser Aluminum
KALU
$2.49B
-8,610
Closed -$720K
KBH icon
1399
KB Home
KBH
$3.41B
-681,086
Closed -$8.4M
KMI icon
1400
Kinder Morgan
KMI
$69B
-300,000
Closed -$4.48M

Similar funds

Dmitry Balyasny's Q1 2016 Portfolio in Review

As of Q1 2016, Dmitry Balyasny held 1,764 positions worth $16.8B, up 17% from $14.4B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Dmitry Balyasny deployed $2.2B of net new capital in Q1 2016, opening 564 new positions and adding to 341 existing holdings. Its largest new stake was Norfolk Southern: 1,546,641 shares worth $129M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 18% of assets, up from 16% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $187M trimmed.

  • Dmitry Balyasny's largest Q1 2016 buy was Norfolk Southern: 1,546,641 shares worth $129M.
  • Dmitry Balyasny added most to Marathon Petroleum in Q1 2016, an estimated $152M increase.
  • Dmitry Balyasny's biggest Q1 2016 reduction was Teva Pharmaceuticals, cutting an estimated $187M.
  • Dmitry Balyasny fully exited Union Pacific in Q1 2016, selling an estimated $79.7M.
  • Dmitry Balyasny's ten largest holdings make up 12% of its $16.8B portfolio in Q1 2016.
  • Dmitry Balyasny opened 564 new positions and closed 526 in Q1 2016.
  • Dmitry Balyasny's portfolio value rose 17% quarter-over-quarter to $16.8B.

Based on Balyasny Asset Management's 13F filing for Q1 2016, filed 16 May 2016.